BioSpace News Archive

Drug Development

Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the publication of 20 week data from the Phase 1/2 clinical trial of pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D).

July 14, 2021
·
7 min read
Business

Taro Announces Resignation of Chief Financial Officer

Taro Pharmaceutical Industries Ltd. announced that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021.

July 14, 2021
·
1 min read
Generic Injectable Market - Growing focus on the Development of Cost-effective Treatment for Rare Diseases is Major Factor Driving the Industry Growth

Injectable usually refers to a drug delivery system and acts as an alternative to oral drugs.

July 14, 2021
·
5 min read
Laboratory Balances and Scales Market: Increase in Number of Research Pipelines of Pharma-Biotech Companies and Contract Research Organizations

The laboratory balances and scales market is expected to reach US$ 2,131.14 million in 2028 from US$ 1,463.53 million in 2021. The market is estimated to grow with a CAGR of 5.5% from 2021-2028.

July 14, 2021
·
4 min read